Regulus Therapeutics Inc. (NASDAQ:RGLS)‘s stock had its “hold” rating reiterated by Needham & Company LLC in a note issued to investors on Tuesday.
The analysts wrote, “Regulus reported 3Q17 financial results last wk and we met w/ mgmt for an update today. Both planned clinical trials of RG-012 in Alport Syndrome pts are now underway and an IND has been submitted for RGLS4326 in Autosomal Dominant Polycystic Kidney Disease. Mgmt has identified male X-linked Alport Syndrome as target pt population for clinical development going forward, due to rapid and homogeneous disease progression. We expect top-line results from 10- patient RG-012 biopsy trial early next yr and from 40-patient RG-012 HERA Phase 2 efficacy trial in early 2019. Maintain HOLD, awaiting more data from lead RG-012 program, but also note encouraging progression of platform/ pipeline behind it.””
Several other analysts have also recently commented on the company. Zacks Investment Research upgraded Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a research report on Tuesday, October 10th. Wedbush reiterated an “ourperform” rating and set a $4.00 price target on shares of Regulus Therapeutics in a research report on Monday, August 7th. Finally, Chardan Capital cut Regulus Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 2nd. One research analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $2.60.
Shares of Regulus Therapeutics (NASDAQ:RGLS) traded down $0.03 on Tuesday, hitting $0.91. The company had a trading volume of 573,200 shares, compared to its average volume of 881,557. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.77 and a quick ratio of 6.77. Regulus Therapeutics has a 52-week low of $0.79 and a 52-week high of $3.38.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Week Herald and is owned by of Week Herald. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://weekherald.com/2017/11/14/regulus-therapeutics-inc-rgls-rating-reiterated-by-needham-company-llc.html.
A number of large investors have recently modified their holdings of the business. South Dakota Investment Council grew its holdings in Regulus Therapeutics by 37.1% in the 3rd quarter. South Dakota Investment Council now owns 1,820,027 shares of the biopharmaceutical company’s stock valued at $2,275,000 after buying an additional 492,969 shares in the last quarter. Candriam Luxembourg S.C.A. acquired a new position in shares of Regulus Therapeutics in the 3rd quarter valued at $750,000. NEA Management Company LLC acquired a new position in shares of Regulus Therapeutics in the 3rd quarter valued at $13,737,000. Victory Capital Management Inc. acquired a new position in shares of Regulus Therapeutics in the 3rd quarter valued at $347,000. Finally, EcoR1 Capital LLC lifted its stake in shares of Regulus Therapeutics by 145.6% in the 2nd quarter. EcoR1 Capital LLC now owns 3,709,144 shares of the biopharmaceutical company’s stock valued at $3,656,000 after purchasing an additional 2,199,144 shares during the last quarter. Institutional investors own 33.45% of the company’s stock.
About Regulus Therapeutics
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.